The Netherlands


Every year, roughly 900,000 children around the world under the age of five lose their lives to pneumonia, a preventable and easily treatable disease. In low-resource settings, the scarcity of doctors and nurses, coupled with a lack of training among healthcare workers, results in hundreds of thousands of unnecessary deaths. The main reason being misclassification of respiratory rates, leading to incorrect pneumonia diagnosis.


Reducing the child mortality rate from pneumonia hinges on the availability of reliable and easy-to-use diagnostic tools. Traditional methods, like counting breaths with pen or paper, are not only time-consuming but are also prone to errors.


ChARM, otherwise known as the Children’s Automated Respiration Monitor, is a battery-powered breathing rate monitor. This device enables health workers to accurately diagnose pneumonia with children under five, so a simple, cost-effective treatment using widely available medication can be put in motion.


With Philips as a partner the future looks promising. So what’s next? ChARM is currently in the phase of a slight redesign and preparing the necessary steps for recertification. After this they will resume production, so the device can be easily available where it’s needed most.

Meet the team


Maarten Neve


Pieter Wijffels (1)

Pieter Wijffels

Venture Partner

Pieter joined NLC in April 2020 as a Venture Partner. Before joining NLC, he spent 15 years at Philips, bringing innovation to life across the globe. He enjoys working in fast-paced environments and supporting initiatives that truly improve people’s lives.